Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

In the same way weight varies from person to person, so do the best weight loss strategies. While some people succeed with ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...